Following the general trend of the other SLRPs, nephrocan has also been reported to function as an endogenous inhibitor of canonical TGF-β signaling, exerting its tumor suppressive function through negative regulation of phosphorylated SMAD3 (Figure 4D) [138]. The gene discussed is TGFB1; the disease is neoplasm.